VIDEO: Second-line tepotinib plus osimertinib benefits metastatic EGFR-mutated NSCLC
Healio spoke with Melina Elpi Marmarelis, MD, about data from the INSIGHT 2 trial presented at this year’s International Association for the Study of Lung Cancer World Conference on Lung Cancer.
The study assessed the use of tepotinib (Tepmetko, Merck/EMD Serono) plus osimertinib (Tagrisso, AstraZeneca) in patients with EGFR-mutated, MET-amplified NSCLC who experienced disease progression after receiving osimertinib.
“They found a pretty impressive overall response rate of 50%, a median PFS of 5 months and a median duration of response of 8.5 months,” Melina Elpi Marmarelis, MD, medical director of the Penn Mesothelioma Program and an assistant professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania, told Healio.
“This impressive overall response rate as well as a fairly good PFS and median duration of response make it a nice option for patients in the second-line setting that just adds another pill to their treatment,” she added.
Collapse
Kim TM, et al. Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following 1L osimertinib: INSIGHT 2 primary analysis. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer; Sept. 9-12, 2023; Singapore.